“Human Milk oligosaccharides (HMOs)” are collectively called a structure of diverse unconjugated glycan’s that are found in and distinct to human breast milk, despite not actually digestible by human infants. HMOs activity as a prebiotic are favoring to initiate commensal bacteria. HMOs also work as anti-adhesives that intercept the attachment of microbial pathogens to mucosal surfaces. Human milk oligosaccharides are prepared by numerous processes which necessitates the usage of several chemicals, enzymes and microbes. The human milk oligosaccharides technology is very difficult and costly, therefore is their large scale production. Key players in the industry have been raising investments on R&D for low-cost production and the initiation of new technologies for product synthesis. The net market for Human Milk oligosaccharides (HMOs) is estimated to be $XX billion in 2016 and is forecast to cross $XX billion by 2023 with a CAGR of $XX% between 2017 and 2023.
Growing innovation of new technologies in “Human Milk oligosaccharides (HMOs)” is increasing the demand for Human Milk oligosaccharides (HMOs) globally. The market for Human Milk oligosaccharides (HMOs) is analyzed by various regions through its applications such as Food & Beverages, Food Supplements and others.
The market for “Human Milk oligosaccharides (HMOs)” is segmented by regions into North America, Europe, Asia-Pacific and Rest of the World. Key market players are profiled with attributes of company overview, business strategies and product portfolio.
Sample Companies Profiled in this Report are:
- Elicityl S.A.
- Glycom A/S
- Glycosyn LLC